MAP3K5 and metabolic dysfunction-associated steatohepatitis: However, the apoptosis signal-regulating kinase 1 inhibitor selonsertib was not found to improve fibrosis or facilitate NASH resolution in NASH patients with bridging (F3) fibrosis (6 mg, n = 321; 18 mg, n = 322) or cirrhosis (F4) (6 mg, n = 351; 18 mg, n = 354) compared to placebo (n = 159 and n = 172, respectively) (NCT03053050 and NCT03053063) [150].